Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of RYONCIL in adults and adolescents, who are refractory to both corticosteroids and a second line agent such as ruxolitinib, for whom there are no approved therapies

Next Previous
X
Search
Trial Profile

A phase III trial of RYONCIL in adults and adolescents, who are refractory to both corticosteroids and a second line agent such as ruxolitinib, for whom there are no approved therapies

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remestemcel-L (Primary)
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 21 Nov 2023 According to a Mesoblast media release, Prior to implementation, the clinical trial protocol will be reviewed by two independent National Heart, Lung, and Blood Institute (NHLBI)-appointed committees. Mesoblast will then submit the final protocol to FDA, as agreed at the Type A meeting with FDA
    • 21 Nov 2023 According to a Mesoblast media release, The BMT CTN is funded by the United States National Institutes of Health.
    • 02 Nov 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top